Patents by Inventor Laurent Meijer
Laurent Meijer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230167104Abstract: The present invention relates to a compound of formula (I) wherein R1 represents a (C1-C6)alkyl group, a spiro(C5-C11)bicyclic ring, a fused phenyl group, a substituted phenyl group, a R?-L- group, wherein L is either a single bond or a (C1-C3)alkanediyl group, and R? represents a (C3-C8)cycloalkyl group, abridged (C6-C10)cycloalkyl group, a (C3-C8)heterocycloalkyl group, or a (C3-C8)heteroaryl group, or a R?-L- group wherein L is a (C1-C3)alkanediyl group, and R? is an optionally substituted phenyl group, and wherein R2 represents a hydrogen atom or a (C1-C3)alkyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates.Type: ApplicationFiled: April 29, 2021Publication date: June 1, 2023Inventors: Emmanuel DEAU, Pascal GEORGE, Laurent MEIJER, Frédéric MIEGE
-
Patent number: 11472807Abstract: Compound of formula (I) and its addition salts with pharmaceutically acceptable acids, and methods in which an effective amount of the compound or any pharmaceutically acceptable salt thereof is administered (as a medicament) to an individual in need thereof.Type: GrantFiled: April 9, 2018Date of Patent: October 18, 2022Assignees: COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, PERHA PHARMACEUTICALSInventors: Aloïse Mabondzo, Charlotte Leuxe, Anne-Cécile Guyot, Nassima Oumata, Laurent Meijer
-
Publication number: 20220160716Abstract: A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases. A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases.Type: ApplicationFiled: March 20, 2020Publication date: May 26, 2022Applicants: SORBONNE UNIVERSITE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), MANROS THERAPEUTICSInventors: Thomas FALGUIERES, Virginie VAUTHIER, Laurent MEIJER, Nassima OUMATA
-
Publication number: 20200354364Abstract: Compound of formula (I) and its addition salts with pharmaceutically acceptable acids, and methods in which an effective amount of the compound or any pharmaceutically acceptable salt thereof is administered (as a medicament) to an individual in need thereof.Type: ApplicationFiled: April 9, 2018Publication date: November 12, 2020Applicants: COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, PERHA PHARMACEUTICALSInventors: Aloïse MABONDZO, Charlotte LEUXE, Anne-Cécile GUYOT, Nassima OUMATA, Laurent MEIJER
-
Patent number: 10561661Abstract: A method for treatment of disease by reduction in macrophages-mediated bacterial killing, including administration to patients in need a compound of formula (I): wherein A is N or CH; B is NO, or S; R1 is H, (C1-C4)alkyl group, methyl(C1-C6)cycloalkyl group or (C1-C6)cycloalkyl group; R2 is an aryl, arylmethyl group or methylheteroaryl group as methylpyridine and methylthiophene; R3 is absent when B is O or S, or is H or (C1-C4)alkyl group when B is N; R4 is (C1-C5)alkyl group or (C1-C4)cycloalkyl group, groups bearing a carboxylic acid group, and (C1-C5)alkyl group or (C1-C4)cycloalkyl substituted by hydroxyl group, halogen group or methoxy group, when B is N, R3 and R4 can together form a 5- or 6-membered heterocycle substituted by carboxylic acid group, substituted by a halogen atom, hydroxyl group, methoxy group or hydroxymethyl group, or pharmaceutically acceptable salt. Also provided are new compounds relating to this use.Type: GrantFiled: February 17, 2015Date of Patent: February 18, 2020Assignees: MANROS THERAPEUTICS, UNIVERSITY OF CHICAGOInventors: Laurent Meijer, Nassima Oumata, Hervé Galons, Aida Gabdoulkhakova, Vladimir Riazanski, Deborah Nelson
-
Publication number: 20150320753Abstract: A method for treatment of disease by reduction in macrophages-mediated bacterial killing, including administration to patients in need a compound of formula (I): wherein A is N or CH; B is NO, or S; R1 is H, (C1-C4)alkyl group, methyl(C1-C6)cycloalkyl group or (C1-C6)cycloalkyl group; R2 is an aryl, arylmethyl group or methylheteroaryl group as methylpyridine and methylthiophene; R3 is absent when B is O or S, or is H or (C1-C4)alkyl group when B is N; R4 is (C1-C5)alkyl group or (C1-C4)cycloalkyl group, groups bearing a carboxylic acid group, and (C1-C5)alkyl group or (C1-C4)cycloalkyl substituted by hydroxyl group, halogen group or methoxy group, when B is N, R3 and R4 can together form a 5- or 6-membered heterocycle substituted by carboxylic acid group, substituted by a halogen atom, hydroxyl group, methoxy group or hydroxymethyl group, or pharmaceutically acceptable salt. Also provided are new compounds relating to this use.Type: ApplicationFiled: February 17, 2015Publication date: November 12, 2015Inventors: Laurent MEIJER, Nassima OUMATA, Hervé GALONS, Aida GABDOULKHAKOVA, Vladimir RIAZANSKI, Deborah NELSON
-
Patent number: 8999955Abstract: The invention relates to kinase inhibitors of the formula (I) in which —R1 to R4?H; ether or polyether, amino; NO2; NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; —R5=—OH; halogen; —OR with R such as defined above; OH-carbamate; OH-carbonate; NH2, NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; N(R9,R10); —R5??H or a C1-C12 alkyl, —R6?H; R; (R or R?)3—Si, with R such as defined above; optionally substituted aryl, heteroaryl; halogen (iodine); alkynyl; —R7 and R8?H, C1-C12 alkyl; —R9 and R10?H, R (or R?) such as defined above. These compounds can be used as kinase inhibitors in particular for treating cancer.Type: GrantFiled: January 19, 2009Date of Patent: April 7, 2015Assignee: Centre National de la Recherche ScientifiqueInventors: Philippe Olivier Belmont, Laurent Meijer, Philip Cohen, Amaury Patin, Johann Bosson, Peter Gregory Goekjian
-
Patent number: 8829203Abstract: Indirubin derivatives of formula (I) wherein R represents -(A)n- R1 or —CO—N(R2,R3) with •A being C1-C5 alkylene group, optionally substituted by one or several A1 radical, A1 being an halogen Br, OH, OR4 or NH2, R4 being C1-C5 alkyl; —R1 being halogen, OH, N(R2, R3); R2 and R3, identical or different, being C1-C5 alkyl, optionally substituted by A1 such as above defined, or R2 and R3 are part of a cycle with 5 or 6 elements optionally comprising another heteroatom such as O or N; •n=1?5. It also relates to the biological application thereof.Type: GrantFiled: July 21, 2009Date of Patent: September 9, 2014Assignee: Centre National de la Recherche Scientifique (CNRS)Inventors: Laurent Meijer, Leandros Skaltsounis, Emmanuel Mikros, Prokopios Magiatis, Carl Johnson
-
Patent number: 8691982Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R1 is a (C1-C6)alkyl or (C3-C6)cycloalkyl group; R2 is a (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkenyl, (C1-C6)fluoroalkyl, (C1-C3)fluoroalkoxy, or (C1-C6)alkoxy(C1-C6)alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NRaRb group, where Ra and Rb are independently a hydrogen atom or a (C1-C3)alkyl group; or a pyrrolidinylmethyl group substituted with one to three hydroxyl groups; R9 is the same as R2 or hydrogen; the R2 and R9 groups independently being substitutable with an —OCOR3 group, where R3 is a natural or unnatural amino acid derivative or a piperidyl group; alternatively, R2 and R9 together form a heterocyclic compound; X and Y are independently a substitutable phenyl or heteroaryl group, the heteroaryl group being a thienyl, pyridyl, pyrimidinyl, thiazolyl, pyrrolyl, or furanyl group; and R6 is a hydrogen or a (C1-C3)alkyl group.Type: GrantFiled: March 11, 2010Date of Patent: April 8, 2014Assignees: Centre National de la Recherche Scientifique, Universite Paris Descartes, Universite Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Laurent Meijer, Hervé Galons, Benoit Joseph, Florence Popowycz, Nassima Oumata
-
Patent number: 8563588Abstract: Imidazolone derivatives, as medicaments, of formula wherein: R1?H, C1 to C5 alkyl, aryl or a 5- or 6-membered heterocyclic group; Ar1=optionally substituted aryl or an aromatic heterocycle; R?R2—S—, R3—HN—, R4COHN or Ar2, with R2=a C1-C5 alkyl, vinyl or vinyl(C1-C5)alkyl, nitrile or nitrile(C1-C5)alkyl, aryl or benzyl radical, which are optionally substituted; R3=the meanings given above and H; Ar2=substituted or unsubstituted aryl.Type: GrantFiled: August 1, 2008Date of Patent: October 22, 2013Assignees: Universite de Rennes 1, Centre National de la Recherche Scientifique (C.N.R.S.)Inventors: Francois Carreaux, Jean-Pierre Bazureau, Steven Renault, Laurent Meijer, Olivier Lozach
-
Patent number: 8552053Abstract: The invention relates to new 3?-, 7-substituted-indirubins of formula (I) wherein R represents N—OH, N—O-alkyl or N—O—CO-alkyl, NO—(Ra)n1-Het, N—O—(Y)n1—N Ra Rb, N—O—CO—N(Rb Rc), radical with Het representing an aliphatic nitrogeneous heterocycle, Y being an optionally substituted —CH2— radical, n1 being 1 to 3, and X is an halogen atom selected in the group comprising F, Cl, Br, I, and Z is H or CH3 and the salts thereof.Type: GrantFiled: December 21, 2006Date of Patent: October 8, 2013Assignees: Centre National de la Recherche Scientifique, University of Pierre and Marie Curie (Paris 6), University of Rennes 1, University of Lleida, Universite d'AthenesInventors: Laurent Meijer, Karima Bettayeb, Alexios-Le-Andros Skaltsounis, Prokopios Maglatis, Jacint Boix, Judit Ribas
-
Patent number: 8492420Abstract: The invention relates to the use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of formula (I): where R2, R6 and R9, independently=halogen, a R—NH—, R—NH—NH—, NH2—R?—NH or R—NH—R?—NH— group, where R=straight or branched chain saturated or unsaturated alkyl, aryl, cycloalkyl, or heterocyclyl group, R?=straight or branched chain, saturated or unsaturated alkylene, arylene or cycloalkylene, R and R? each include 1 to 8 carbon atoms optionally substituted with one or more —OH, halogen, amino or alkyl groups, R2 furthermore may be a heterocycle optionally with a straight or branched chain saturated or unsaturated alkyl, aryl or cycloaryl or a heterocycle optionally substituted by one or more —OH, halogen, amino or alkyl groups, R9 furthermore may be a straight or branched chain saturated or unsaturated alkyl, aryl or cycloalkyl and R2 and R9 furthermore may be hydrogen with the exceptionType: GrantFiled: April 12, 2007Date of Patent: July 23, 2013Assignees: Centre National de la Recherche Scientifique-CNRS, Universite de PoitiersInventors: Frédéric Becq, Laurent Meijer
-
Patent number: 8450342Abstract: The invention relates to trisubstituted or tetrasubstituted imidazo[4,5b]pyridines, to their uses as well as to a process for manufacturing them. The compounds of the invention are imidazo[4,5b]pyridines. The first general synthesis of 3,5,7 imidazo[4,5b]pyridines is disclosed in the description. The invention founds application, in particular, in the pharmaceutical field.Type: GrantFiled: February 19, 2010Date of Patent: May 28, 2013Assignees: Centre Nationale de la Recherche Scientifique, Universite de Rennes 1, Universite Paris DescartesInventors: Laurent Meijer, Karima Bettayeb, Herve Galons, Luc Demange, Nassima Oumata
-
Patent number: 8431583Abstract: At least one compound of following formula I: in which: X is C or N, Y is CH3 or OH, and Z is H or CH3, or one of its pharmaceutically acceptable salts, hydrates, esters or isomers, for use in the manufacture of a medicament to treat pathologies in which an imbalance between cell division and apoptosis is involved.Type: GrantFiled: September 12, 2008Date of Patent: April 30, 2013Assignees: Centre National de la Recherche Scientifique, Universite de Rennes 1, Universite Paris Descartes, Universite de Bretagne Occidentale, Centre Hospitalier Universitaire de BrestInventors: Laurent Meijer, Karima Bettayeb, Hervé Galons, Nassima Oumata, Christian Berthou, Karine Lester
-
Patent number: 8318707Abstract: The present invention relates to the use of 6-(benzyl-amino)-2(S)-[[1-(hydroxymethyl) propyl]amino]-9-isopropylpurine) or at least one of its pharmaceutical acceptable salts for manufacturing a medication intended for the prevention and/or treatment of neurological diseases, in particular associated with neurological lesions.Type: GrantFiled: March 30, 2007Date of Patent: November 27, 2012Assignee: NeurokinInventors: Serge Timsit, Bénédicte Menn, Laurent Meijer
-
Publication number: 20120184557Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R1 is a (C1-C6)alkyl or (C3-C6)cycloalkyl group; R2 is a (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkenyl, (C1-C6)fluoroalkyl, (C1-C3)fluoroalkoxy, or (C1-C6)alkoxy(C1-C6)alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NRaRb group, where Ra and Rb are independently a hydrogen atom or a (C1-C3)alkyl group; or a pyrrolidinylmethyl group substituted with one to three hydroxyl groups; R9 is the same as R2 or hydrogen; the R2 and R9 groups independently being substitutable with an —OCOR3 group, where R3 is a natural or unnatural amino acid derivative or a piperidyl group; alternatively, R2 and R9 together form a heterocyclic compound; X and Y are independently a substitutable phenyl or heteroaryl group, the heteroaryl group being a thienyl, pyridyl, pyrimidinyl, thiazolyl, pyrrolyl, or furanyl group; and R6 is a hydrogen or a (C1-C3)alkyl group.Type: ApplicationFiled: March 11, 2010Publication date: July 19, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE PARIS DESCARTESInventors: Laurent Meijer, Hervé Galons, Benoit Joseph, Florence Popowycz, Nassima Oumata
-
Patent number: 8163762Abstract: This invention provides 2-, 6, and 9-substituted purine derivatives, particularly 2(1-R hydroxymethylpropylamino)-6-benzylamino-9-isopropyl purine, having, in particular, antiproliferative properties, and suitable for use as pharmaceutical compositions and herbicidal compositions. Also provided are pharmaceutical compositions and herbicidal compositions comprising the 2-, 6, and 9-substituted purine derivatives, and methods of treatment using the 2-, 6, and 9-substituted purine derivatives.Type: GrantFiled: December 23, 2009Date of Patent: April 24, 2012Assignees: Centre National de la Recherche Scientifique (CNRS), Institute of Experimental Botany, Academy of Science of the Czech RepublicInventors: Laurent Meijer, Emile Bisagni, Michel Legraverend, Miroslav Strnad
-
Publication number: 20120095022Abstract: The present invention relates to compounds having the following general formula (I): wherein: A represents a SO2 or CX group, X representing O or S; R1, R2, R?, R4 represent in particular H, R represents in particular an alkyl group or an aryl group, as well as to the pharmaceutically acceptable salts thereof, the compound of formula (I) taking the form of a pure stereoisomer or an enantiomer and/or diastereoisomer mixture, including racemic mixtures.Type: ApplicationFiled: March 11, 2010Publication date: April 19, 2012Applicants: UNIVERSITE D'ORLEANS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Sylvain Cesar Leonce Routier, Gerald Guillaumet, Rajaa Boulahjar, Laurent Meijer, Matteo Chiurato
-
Patent number: 8106050Abstract: The invention relates to pyrrolo[2,3b]-pyrazine derivatives having the general Formula (I) wherein R2 and R3 are identical or different and represent H, C1-C6 alkyl, said alkyl being a straight or branched-chain alkyl, which can be substituted, R6 is an optionally substituted aromatic cycle Ar or a cycloalkyl, said cycloalkyl being optionally substituted by an aryl group which can also be substituted, R7 is H, C1-C6 alkyl, (alk.)n-hal., CH2-CH?CH2, CH2-cycloalkyl, CH2-Ar, with “alk.” being a C1-C6 alkylene group, n being 1-6, Z is H or CH3. Application as active principle of pharmaceutical compositions, particularly for treating or preventing neurodegenerative disorders and proliferative disorders.Type: GrantFiled: August 8, 2003Date of Patent: January 31, 2012Assignee: Centre National de la Recherche Scientifique (C.N.R.S.)Inventors: Laurent Meijer, Jean-Michel Vierfond, Yvette Mettey
-
Publication number: 20110136808Abstract: Indirubin derivatives of formula (I) wherein R represents -(A)n- R1 or —CO—N(R2,R3) with •A being C1-C5 alkylene group, optionally substituted by one or several A1 radical, A1 being an halogen Br, OH, OR4 or NH2, R4 being C1-C5 alkyl; —R1 being halogen, OH, N(R2, R3); R2 and R3, identical or different, being C1-C5 alkyl, optionally substituted by A1 such as above defined, or R2 and R3 are part of a cycle with 5 or 6 elements optionally comprising another heteroatom such as O or N; •n=1?5. It also relates to the biological application thereof.Type: ApplicationFiled: July 21, 2009Publication date: June 9, 2011Inventors: Laurent Meijer, Leandros Skaltsounis, Emmanuel Mikros, Prokopios Magiatis, Carl Johnson